Reduction of the risk of failure to achieve blood pressure control in patients with arterial hypertension and coronary heart disease: the role of quercetin
DOI:
https://doi.org/10.14739/2310-1237.2023.1.268435Keywords:
hypertension, s-ICAM-1, sVCAM, endothelin-1, endothelial dysfunction, quercetinAbstract
Aim. Determine the effect of quercetin on predictors of not reaching target blood pressure (BP) levels in patients with arterial hypertension (AH) and coronary heart disease (CHD).
Materials and methods. 120 patients with stable coronary heart disease and hypertension of the II stage 2–3 degrees (66 women and 54 men) were examined. The patients were divided into 2 groups: Group I – 58 patients who, in addition to basic therapy (ramipril/amlodipine), received quercetin (Corvitin®), Group II – 62 patients who received only basic antihypertensive therapy. The parameters of daily blood pressure monitoring, blood lipid spectrum, C-reactive protein, the concentration of adhesion molecules (s-VCAM, s-ICAM-1), levels of endothelin-1 (ET-1), IL-1, IL-6, TNF-α were determined. Statistical processing of materials was carried out using the following programs: Minitab 21.0, StatPlus Pro 7.6.5, Wizard Pro, Jamovi, MedCalc.
Results. We have established that the risk of not reaching the target level of daily SBP in the group of basic treatment of hypertension (group II) significantly increases with exceeding the level of LDL >4.0 mmol/l (by 3.6 times), an increase in the level of IL-6 >7 ng/ml (by 10 times), an increase in the level of TNF-α >9 pg/ml (by 7 times), an increase in the level of VCAM >1100 ng/ml (by 2.4 times). In the group of people who additionally took quercetin (group I), with an increase in the level of ET-1 >1.1 pg/ml, the risk of failure to reach the target SBP increases by 2.6 times, in the II group – by 3.5 times toward to daily SBP and 8.6 times – toward to daily DBP. We found out that an increase in the concentration of IL-6 > 7 ng/mg significantly increases the risk of arrhythmias by 6 times in group II.
Conclusions. When quercetin is used, it is possible to achieve the target values of SBP (daily, daytime, nighttime) and DBP (daily, daytime, nighttime) in a significantly higher proportion of patients compared with those who are prescribed only standard antihypertensive therapy. Quercetin has an endothelial protective effect, as evidenced by a significant decrease in the levels of vascular endothelial adhesion molecules (s-VCAM), type I intercellular adhesion molecules (s-ICAM-1), ET-1, IL-1, IL-6, TNF-α. The additional use of quercetin against the background of standard antihypertensive therapy significantly reduces the risk of failure to achieve the target levels of SBP, DBP and the risk of heart rhythm disturbances even against the background of increased levels of proinflammatory cytokines and markers of endothelial dysfunction.
References
Boichuk, H. R., Myronets, O. I., & Plesh, I. A. (2019). Osnovni faktory ryzyku prohresuvannnia hipertonichnoi khvoroby [The main risk factors for the progression of hypertension]. Bimco Journal. Abstract book of the congress BIMCO (pp. 187-187). [in Ukrainian].
Vantiukh, N. V., Lemko, O. I., & Reshetar, D. V. (2020). Khronichna bronkhialna obstruktsiia ta endotelialna dysfunktsiia: deiaki imunolohichni aspekty vzaiemodii [Chronic bronchial obstruction and endothelial dysfunction: some immunological aspects of the interaction]. Astma ta alerhiia, (3), 14-21. [in Ukrainian]. https://doi.org/10.31655/2307-3373-2022-3-14-21
Vatseba, M. O., Haliuk, N. M., & Havrysh, I. M. (2021, December 28). Endotelialna dysfunktsiia u cholovikiv z arterialnoi hipertenziieiu ta komorbidnoiu patolohiieiu [Endothelial dysfunction in men with arterial hypertension and comorbid pathology]. Modern medicine: the use of creative industries in the healthcare system. International scientific conference (pp. 24-26). Medical University of Lublin. [in Ukrainian]. https://doi.org/10.30525/978-9934-26-182-4-5
Vynnychenko, L. B., & Pryvalova, A. O. (2017). Endotelialna dysfunktsiia ta arterialna ryhidnist u khvorykh na khronichne obstruktyvne zakhvoriuvannia [Endothelial dysfunction and arterial stiffness in patients with chronic obstructive disease]. Aktualni pytannia teoretychnoi ta klinichnoi medytsyny. Abstracts of reports of the 5th international scientific and practical conference (pp. 225-225). Sumy: Sumy State University. [in Ukrainian].
Zaremba, Ye. Kh., Zaremba-Fedchyshyn, O. V., & Prokosa, M. I. (2021). Otsinka efektyvnosti metabolichnoi terapii v rozvytku adhezyvnoi dysfunktsii endoteliiu u khvorykh na arterialnu hipertenziiu [Evaluation of effectiveness of metabolic therapy in the development of adhesive dysfunction of endothelia in patients with arterial hypertension]. Zdobutky klinichnoi i eksperymentalnoi medytsyny, (2), 77-82. [in Ukrainian]. https://doi.org/10.11603/1811-2471.2021.v.i2.11822
Zaremba, Ye. Kh., Zaremba-Fedchyshyn, O. V., Prokosa, M. I. (2020). Vplyv metabolichnoi terapii na dynamiku dobovoho monitorynhu arterialnoho tysku u khvorykh na arterialnu hipertenziiu. [The influence of metabolic therapy on daily blood pressure monitoring dynamics in hypertensive patients]. Simeina medytsyna, (4), 63-66. [in Ukrainian]. https://doi.org/10.30841/2307-5112.4.2020.217673
Nemish, I. L. (2022). Endotelialna dysfunktsiia u khvorykh na khronichnyi koronarnyi syndrom, khronichne obstruktyvne zakhvoriuvannia lehen ta ozhyrinnia [Endothelial dysfunction in patients with chronic coronary syndrome, chronic obstructive pulmonary disease and obesity]. 103rd final scientific and practical conference with the international participation of professors and teaching staff of Bukovinian State Medical University (pp. 160-161). [in Ukrainian].
Moibenko, O. O. (2015). Bioflavonoidy yak orhanoprotektory (kvertsetyn, korvityn, kvertyn) [Bioflavonoids as organoprotectors (quercetin, corvitin, quertin)]. Naukova dumka. [in Ukrainian].
Korkushko, O. V., Antoniuk-Shchehlova, I. A., Naskalova, S. S., Bondarenko, O. V., Hryb, O. M., Shatylo, V. B., & Koshel, N. M. (2021). Endoteliiprotektorni ta antyhipoksychni vlastyvosti kvertsetynu u patsiientiv pokhyloho viku z metabolichnym syndromom. [Endotheliumprotectiv and antihypoxic properties of quercetin in elderly patients with metabolic syndrome]. Zaporozhye medical journal, 23(2), 195-201. [in Ukrainian]. https://doi.org/10.14739/2310-1210.2021.2.228707
Parkhomenko, A. N. (2008). Metabolicheskaya terapiya, ili kardioprotektsiya pri ishemicheskoi bolezni serdtsa: itogi i perspektivy [Metabolic therapy, or cardioprotection in ischemic heart disease: results and prospects]. Ukrainskyi medychnyi chasopys, (4), 15-19. [in Russian].
Polianska, O. S., & Amelina, T. M. (2011). Endotelialna dysfunktsiia pry ishemichnii khvorobi sertsia v poiednanni z suputnoiu patolohiieiu [Endothelial dysfunction in coronary heart disease in combination with concomitant pathology]. Aktualni pytannia vnutrishnoi medytsyny. Proceedings of the scientific and practical conference (pp. 136-137). [in Ukrainian].
Ryzhkova, N. O., Gavrilenko, T. I., & Parkhomenko, O. M. (2016). Korvityn znyzhuie vysokyi vmist miieloperoksydazy v plazmi krovi khvorykh na hostryi infarkt miokarda. [Korvitin reduces the high maintenance of myeloperoxidase in plasma of blood of patients with the acute infarct of myocardium]. Fiziolohichnyi zhurnal, 62(2), 87-93. [in Ukrainian]. https://doi.org/10.15407/fz62.02.087
Ministry of Health of Ukraine. (2016, September 23). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy “Stabilna ishemichna khvoroba sertsia”. Nakaz vid 23.09.2016 No. 994 [Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care “Stable ischemic heart disease” (No. 994)]. [in Ukrainian].
Ministry of Health of Ukraine. (2021, December 23). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy “Stabilna ishemichna khvoroba sertsia”. Nakaz vid 23.12.2021 No. 2857 [Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care “Stable ischemic heart disease” (No. 2857)]. https://zakon.rada.gov.ua/rada/show/v2857282-21#Text
Kazakov, Yu. M., Chekalina, N. I., Burmak, Yu. H., Petrov, Ye. Ie., Borysova, Z. O., & Manusha, Yu. I. (2017). Porivnialna otsinka vplyvu resveratrolu ta kvertsetynu na pokaznyky systemnoho zapalennia u khvorykh na ishemichnu khvorobu sertsia [Comparative assessment of the effect of resveratrol and quercetin on indicators of systemic inflammation in patients with coronary heart disease]. Profilaktyka neinfektsiinykh zakhvoriuvan: fokus na komorbidnist. Materials of Scientific and Practical Conference (pp. 65-65). Kharkiv. [in Ukrainian].
Shalimova, A. S. (2014). Endotelialna dysfunktsiia ta yii korektsiia u patsiientiv z hipertonichnoiu khvoroboiu i tsukrovym diabetom 2-ho typu [Endothelial dysfunction and its correction in patients with essential hypertension and type 2 diabetes mellitus]. Mizhnarodnyi endokrynolohichnyi zhurnal, (2), 33-39. [in Ukrainian].
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., Lip, G. Y. H., … ESC Scientific Document Group (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European heart journal, 39(33), 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Aksenov, E. V. (2019). Endotelialna dysfunktsiia ta shliakhy yii profilaktyky pry provedenni renthenendovaskuliarnykh protsedur po rekanalizatsii koronarnykh arterii [Endothelial Dysfunction and Ways of its Prevention during Percutaneous Coronary Interventions by Recanalization of Coronary Arteries]. Ukrainskyi zhurnal medytsyny, biolohii ta sportu, 4(5), 102-108. [in Ukrainian].
DeSouza, C. A., Dengel, D. R., Macko, R. F., Cox, K., & Seals, D. R. (1997). Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. American journal of hypertension, 10(12 Pt 1), 1335-1341. https://doi.org/10.1016/s0895-7061(97)00268-9
Elliott, W. J. (2012). Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. Yearbook of Medicine, 2012, 338-340. https://doi.org/10.1016/s0084-3873(12)00261-1
Guragac Dereli, F. T., & Belwal, T. (2020). Quercetin. In Naturally Occurring Chemicals against Alzheimer’s Disease (pp. 109-115). Elsevier. https://doi.org/10.1016/B978-0-12-819212-2.00008-6
Hedayat, M., Mahmoudi, M. J., Rose, N. R., & Rezaei, N. (2010). Proinflammatory cytokines in heart failure: double-edged swords. Heart failure reviews, 15(6), 543-562. https://doi.org/10.1007/s10741-010-9168-4
Troncoso, M. F., Ortiz-Quintero, J., Garrido-Moreno, V., Sanhueza-Olivares, F., Guerrero-Moncayo, A., Chiong, M., Castro, P. F., García, L., Gabrielli, L., Corbalán, R., Garrido-Olivares, L., & Lavandero, S. (2021). VCAM-1 as a predictor biomarker in cardiovascular disease. Biochimica et biophysica acta. Molecular basis of disease, 1867(9), 166170. https://doi.org/10.1016/j.bbadis.2021.166170
Ferreira, I., Hovind, P., Schalkwijk, C. G., Parving, H. H., Stehouwer, C. D. A., & Rossing, P. (2018). Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. Diabetologia, 61(1), 231-241. https://doi.org/10.1007/s00125-017-4470-5
Lee, K. M., Kang, H. S., Yun, C. H., & Kwak, H. S. (2012). Potential in vitro Protective Effect of Quercetin, Catechin, Caffeic Acid and Phytic Acid against Ethanol-Induced Oxidative Stress in SK-Hep-1 Cells. Biomolecules & therapeutics, 20(5), 492-498. https://doi.org/10.4062/biomolther.2012.20.5.492
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
